De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases

Institutional database search (1999-2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0 center dot 13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0 center dot 67). Treatment-induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0 center dot 61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.